Optimization of a Digital Medicine System in Psychiatry.

BACKGROUND Nonadherence to medication compromises the effectiveness of psychiatric treatments in patients with serious mental illness (SMI). A newly developed digital medicine system (DMS) offers an opportunity to objectively assess and report patient medication adherence. DMS includes a wearable sensor that receives a data signal from a medication tablet with an embedded ingestible sensor after ingestion of the medication and transmits that data to the patient's mobile device to display health care information for the patient and treatment team. METHODS/RESULTS Development of a DMS requires a program that investigates safety, tolerability, and usability of the system in patients with SMI. It necessitates rapid design adaptation of the individual components and the integrated system and human factors studies with the intended users. This article describes the program's methodology and shows results from 3 early studies, conducted in 2013 and 2014, to illustrate diversity of the programs' methodology. First, a standard 28-day study showed minimal skin irritation and demonstrated acceptable wearability of the wearable sensor. Second, a 16-week study provided usability feedback from patients with SMI and caregivers to improve the mobile application. Third, end-to-end bench-level integrated system testing led to multiple substudies of a master protocol (ClinicalTrials.gov identifier: NCT02091882) to investigate various aspects of the system (eg, ingestible sensor detection and latency). CONCLUSIONS To develop a DMS in psychiatry, the system's multiple components must be considered simultaneously using various methodologies. A focus on usability, along with agile evaluation and feedback across studies, provides an optimal strategy for ensuring patient acceptance and successful regulatory review.

[1]  T. Peters-Strickland,et al.  Developing a Digital Medicine System in Psychiatry: Ingestion Detection Rate and Latency Period. , 2016, The Journal of clinical psychiatry.

[2]  R. Baldessarini,et al.  Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials , 2015, The international journal of neuropsychopharmacology.

[3]  Lisa A. Marsch,et al.  Emerging mHealth and eHealth interventions for serious mental illness: a review of the literature , 2015, Journal of mental health.

[4]  George M. Savage,et al.  An Ingestible Sensor for Measuring Medication Adherence , 2015, IEEE Transactions on Biomedical Engineering.

[5]  D. Mohr,et al.  Behavioral intervention technologies: evidence review and recommendations for future research in mental health. , 2013, General hospital psychiatry.

[6]  Roy H Perlis,et al.  First experience with a wireless system incorporating physiologic assessments and direct confirmation of digital tablet ingestions in ambulatory patients with schizophrenia or bipolar disorder. , 2013, The Journal of clinical psychiatry.

[7]  Fleur Fritz,et al.  Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. , 2012, Acta dermato-venereologica.

[8]  John M. Davis,et al.  Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis , 2012, The Lancet.

[9]  Misha Pavel,et al.  Advancing the Science of mHealth , 2012, Journal of health communication.

[10]  Ralph Maddison,et al.  A Development and Evaluation Process for mHealth Interventions: Examples From New Zealand , 2012, Journal of health communication.

[11]  J. Haro,et al.  Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: Results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Study , 2011, Psychiatry Research.

[12]  G. Parker,et al.  Mobile mental health: Review of the emerging field and proof of concept study , 2011, Journal of mental health.

[13]  P. Weiden,et al.  Measurement of psychiatric treatment adherence. , 2010, Journal of psychosomatic research.

[14]  J. M. Christian Bastien,et al.  Usability testing: a review of some methodological and technical aspects of the method , 2010, Int. J. Medical Informatics.

[15]  Alexander L. Miller,et al.  Relationships among subjective and objective measures of adherence to oral antipsychotic medications. , 2007, Psychiatric services.

[16]  Michael B. Spring,et al.  Designing websites for persons with cognitive deficits: Design and usability of a psychoeducational intervention for persons with severe mental illness. , 2007, Psychological services.

[17]  M. Valenstein,et al.  Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. , 2006, The Journal of clinical psychiatry.

[18]  M. Sajatovic,et al.  Treatment adherence with antipsychotic medications in bipolar disorder. , 2006, Bipolar disorders.

[19]  M. Swartz,et al.  Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. , 2006, The Journal of clinical psychiatry.

[20]  Alexander L. Miller,et al.  Defining and assessing adherence to oral antipsychotics: a review of the literature. , 2005, Schizophrenia bulletin.

[21]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[22]  Jan Scott,et al.  Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. , 2002, The American journal of psychiatry.

[23]  Christian R. Dolder,et al.  Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. , 2002, The Journal of clinical psychiatry.

[24]  John H. Draize,et al.  METHODS FOR THE STUDY OF IRRITATION AND TOXICITY OF SUBSTANCES APPLIED TOPICALLY TO THE SKIN AND MUCOUS MEMBRANES , 1944 .